Monoclonal Antibody Therapeutics Market Price, Demand and Growth Monoclonal Antibody Therapeutics Market | Page 2

research by the World Health Organization predicts that the world will witness a 70% spike in the overall cancer cases, of which 60% of the cases will be attributable to Latin America, Asia, and Africa. The incremental approvals in monoclonal antibody products across Europe and the U.S. have also contributed to soaring revenue of the global market. The report by TMR suggests that about five to six monoclonal antibodies are approved each year in these regions. Out of the 60 monoclonal antibodies approved in Europe in 2015, 48 have hit the market. Thus, the widening product portfolio that comes in a broad price range has also played a key role in encouraging the uptake of monoclonal antibody therapeutics. High Cost of Production Dissuades Market Growth Though the market is estimated to have a bright potential, it is likely to be shadowed by a few restraints. The increasing production of biosimilars that are also used for treating various chronic conditions and autoimmune diseases are expected to eat into the market share of monoclonal antibody therapeutics market. Furthermore, the patent cliff of several products is also likely to have a negative impact on the overall earnings of the global market. The market is also anticipated to face a tough challenge due to the high cost of monoclonal antibodies as their production is exceptionally time-consuming and demands strict adherence to rules and regulations. This review is based on Transparency Market Research’s report, titled “Monoclonal Antibody Therapeutics Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast, 2016 - 2024.” To Get Full Detail of The Reports @ http://www.transparencymarketresearch.com/monoclonal- antibody-therapeutics-market.html The monoclonal antibody therapeutics market has been segmented as follows: Monoclonal Antibody Therapeutics Market, by Application  Cancer  Autoimmune diseases  Infection  Hematological diseases  Ophthalmological diseases  Others Monoclonal Antibody Therapeutics Market, by Source  Human  Humanized  Chimeric  Others Monoclonal Antibody Therapeutics Market, by End Users  Hospitals  Private Clinics  Research Institute Monoclonal Antibody Therapeutics Market, by Geography  North America